Clinical Trials
Fox Trial Finder Matched Record Number of Participants in 2025
Fox Trial Finder, the online matching tool from the Michael J. Fox Foundation, connected over 15,000 people with Parkinson's to recruiting clinical trials last year. The tool asks about location, disease stage, and treatment history to suggest studies that might be a good fit. Families report feeling more hopeful after finding a trial that matched their situation. *
michaeljfox.orgNew Trial Focuses on Early-Stage Parkinson's Prevention
A new prevention trial is testing whether a common blood pressure medication can delay or prevent Parkinson's onset in people with early warning signs. The study is enrolling adults over 60 who show prodromal symptoms but have not been diagnosed. Researchers hope to intervene before significant neuron loss occurs. *
clinicaltrials.govVirtual Trial Visits Prove Feasible for Parkinson's Research
A multi-site study found that remote research visits — using video calls and at-home symptom tracking apps — produced reliable data comparable to in-person assessments. This opens the door for rural and homebound patients to participate in trials they couldn't previously access. *
parkinson.org
Breakthrough Treatments
BRAIN Initiative Funds New Dopamine Cell Replacement Project
The NIH's BRAIN Initiative awarded $12 million to develop a lab-grown dopamine neuron therapy for Parkinson's. The project aims to create off-the-shelf cell grafts that can be transplanted without immune suppression. If successful, this could become a one-time procedural treatment. *
nih.govGene Therapy Trial Reports Sustained Symptom Improvement
A five-year follow-up of a Parkinson's gene therapy trial found that participants maintained significant motor symptom improvements without worsening. The therapy delivers genes that increase dopamine production in the brain. No serious side effects were reported in the extended follow-up period. *
medrxiv.orgNew Drug Reduces Tremor Without Increasing Dyskinesia
An experimental medication showed statistically significant tremor reduction in people with Parkinson's without worsening dyskinesia — a common side effect of current levodopa therapy. The drug works through a different biological pathway than dopamine replacement, offering a new approach for people whose tremor no longer responds well to standard treatment. *
news.weill.cornell.edu
Lifestyle Interventions
Dance Therapy Improves Balance and Confidence
A randomized controlled trial of twice-weekly Argentine tango classes showed meaningful improvements in balance and functional mobility for people with mild-to-moderate Parkinson's. Participants also reported greater confidence in walking and reduced fear of falling. Tango's rhythmic cuing from music appears to help with movement initiation. *
pubmed.ncbi.nlm.nih.govProtein Intake Timing May Affect Medication Response
Emerging research suggests that taking levodopa 30 minutes before or 60 minutes after high-protein meals improves absorption and symptom control. Dietitians are now working with neurologists to create personalized meal-timing plans for people experiencing unpredictable medication responses. *
parkinson.orgSleep Quality Linked to Next-Day Motor Performance
A wearable sensor study found that people with Parkinson's who slept fewer than 5 hours per night had 23% worse motor scores the following day. Researchers emphasize sleep hygiene as a critical but often overlooked part of Parkinson's management. Improving sleep could be one of the simplest ways to feel better day-to-day. *
journal.chestnet.org
Emerging Research
AI Model Predicts Progression Using Voice Patterns
An artificial intelligence model trained on voice recordings predicted Parkinson's progression with 85% accuracy in a 200-person study. Voice changes — including softness, monotonicity, and breathiness — appear early and reflect underlying neural changes. This could become a low-cost monitoring tool accessible via smartphone. *
nature.comGut Microbiome Differences Seen Years Before Diagnosis
Researchers found distinct gut bacteria profiles in people who later developed Parkinson's, appearing up to 10 years before motor symptoms. This supports the emerging theory that gut inflammation precedes and may contribute to brain changes in Parkinson's. Gut microbiome testing could eventually identify high-risk individuals for preventive interventions. *
cell.comNew Alpha-Synuclein Biomarker Enables Earlier Detection
Scientists developed a blood test that detects abnormal alpha-synuclein with 90% accuracy in early-stage Parkinson's patients. Currently, Parkinson's diagnosis relies on clinical symptoms that appear after significant neuron loss. This biomarker could allow diagnosis years earlier, when disease-modifying treatments may be most effective. *
sciencedaily.com
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.